Brian Markison
2021
In 2021, Brian Markison earned a total compensation of $1.4M as President and Chief Executive Officer at RVL Pharmaceuticals plc, a 63% decrease compared to previous year.
Compensation breakdown
| Option Awards | $768,750 |
|---|---|
| Salary | $664,615 |
| Total | $1,433,365 |
Markison received $768.8K in option awards, accounting for 54% of the total pay in 2021.
Markison also received $664.6K in salary.
Rankings
In 2021, Brian Markison's compensation ranked 7,443rd out of 12,415 executives tracked by ExecPay. In other words, Markison earned more than 40.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,443 out of 12,415 | 40th |
Division Manufacturing | 3,274 out of 5,505 | 41st |
Major group Chemicals And Allied Products | 1,448 out of 2,375 | 39th |
Industry group Drugs | 1,289 out of 2,096 | 39th |
Industry Pharmaceutical Preparations | 947 out of 1,546 | 39th |
Source: SEC filing on April 25, 2022.
Markison's colleagues
We found three more compensation records of executives who worked with Brian Markison at RVL Pharmaceuticals plc in 2021.
News
RVL Pharmaceuticals plc Former EVP, Research & Development Tina deVries' 2022 pay slips 19% to $561K
April 24, 2023
RVL Pharmaceuticals plc CEO Brian Markison's 2021 pay falls 63% to $1.4M
April 25, 2022
RVL Pharmaceuticals plc CEO Brian Markison's 2020 pay slips 12% to $3.8M
April 26, 2021
RVL Pharmaceuticals plc CEO Brian Markison's 2019 pay jumps 291% to $4.3M
April 20, 2020
RVL Pharmaceuticals plc CEO Brian Markison's 2018 pay slips 10% to $1.1M
April 26, 2019